Clinical Updates on the Treatment of Advanced Cholangiocarcinoma - Episode 22

Perspectives on Treating CCA Moving Forward

May 3, 2021
John L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers

,
R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center

,
Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute

,
Milind Javle, MD, MD Anderson Cancer Center

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

John L. Marshall, MD: Thank you all. We do want to give you one last moment to share your thoughts. Katie, let’s give you first chair.
 

R. Kate Kelley, MD: It’s been an honor to be part of this team. My future perspective on cholangiocarcinoma is that we are going to have a world of new data as the years pass. I see futures in so many of these heterogeneous subsets; they will start classifying and nuancing themselves, whether it’s FGFR2IDH1, or MSI-high, and as we go, we’ll discover more. This will be a complicated but interesting disease that lets us finesse and tailor our treatments to the individual patient’s tumor.
 

John L. Marshall, MD: Sameek?
 

Sameek Roychowdhury, MD, PhD: I would second that sentiment. The care for our patients with cholangiocarcinoma is improving through research and collaborative teamwork across the country, from laboratory and clinical researchers to the computer scientists that look at data. Most importantly, it’s the patients who are participating in our clinical trials, and we’re really grateful for them. We’re hoping that we’ll have even better things to offer them as the years come.
 

John L. Marshall, MD: That’s great, Sameek. Milind, take us home.
 

Milind Javle, MD: This is a very exciting time for the disease. For the first time ever, we had a drug approved last year, and we are on the threshold of other drug approvals within this year. Let’s not forget that management of cholangiocarcinoma is multidisciplinary. Although the focus here is on mutational profiling and NGS [next-generation sequencing], to get true benefit, you have to talk to the interventional radiologist, the radiation oncologist, the surgeon, along with the patient and their family for their wishes.
 

John L. Marshall, MD: I want to thank you all for your time. We know how busy you all are. Sharing this information will impact patients all across the world. I want to thank our viewers for joining, and I hope you found this OncLive Peer Exchange® both useful and informative.

TRANSCRIPT EDITED FOR CLARITY